Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Biotechnology

Healthcare
$7.38 -2.78%

-$0.15 today

Market cap
$2.10B
Beta
0.71
P/E (TTM)
-7.1
EPS (TTM)
-$0.71
52W Low $1.99High $5.32

Volume 1.41M

Average 2.42M

MRVI Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Maravai LifeSciences Holdings, Inc.NASDAQ: MRVI

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development dips below year-ago levels

Q2 FY2026 research & development of $3.7M fell 24.2% year over year, behind the +13.2% change in trailing-twelve-month research & development. Sequentially, it fell 4.8% from the prior quarter. Over 3 fiscal years it compounded at +8.3% a year.

Context

  • Research & development amounted to 12.6% of revenue in FY2025, up 5.1 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -24.2% toward the trailing-twelve-month pace of +13.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.7M-4.8% QoQ
Last fiscal yearDec 2025
$23.33M+21.4% YoY
LTMJun 2026
$21.15M+13.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.2%——
1 year+21.4%——
3-year CAGR+8.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
23.33M USD
Year-over-year change
+21.4%
4-year CAGR
+11.3%

Research & Development vs competitors

How MRVI compares with its peers on the latest reported figures

  • MRVI's LTM Jun 2026 research & development of $21.15M is the 7th highest of the 9 companies compared; the peer median is $46.58M.
  • Its year-over-year change of +13.2% is the 3rd highest of 9, against a peer median of -4.5%.
  • Research & development amounts to 10.1% of revenue for MRVI, versus a peer median of 8.0%.
MRVI Competitors Peer median
Research & Development for MRVI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$261.1M -14.3%+0.0%10.1%
TECHBio-Techne CorporationLTM Sep 2026$96.87M -3.0%+0.8%7.9%
PACBPacific Biosciences of California, Inc.LTM Mar 2026$87.86M -27.1%-20.4%54.9%
RGENRepligen CorporationLTM Jun 2026$55.23M +14.4%+7.2%7.0%
AZTAAzenta, Inc.LTM Sep 2026$37.92M +31.1%+3.7%6.1%
LABStandard BioTools Inc.LTM Mar 2026$22.48M -43.6%-11.4%26.1%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$21.15M +13.2%+8.3%10.1%
NEOGNeogen CorporationLTM Aug 2026$19.76M -5.9%-10.9%2.2%
BLFSBioLife Solutions, Inc.LTM Mar 2026$8.14M +5.5%-20.0%8.2%
Peer median (excluding MRVI) $46.58M-4.5%-5.5%8.0%

Competitors are the stored peer set for MRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue799.24M883M288.95M259.19M185.74M
Cost of Revenue140.56M168.96M148.74M150.88M152.35M
Gross Profit658.68M714.04M140.2M108.31M33.39M
Gross Margin82.4%80.9%48.5%41.8%18.0%
Research & Development15.22M18.37M17.28M19.22M23.33M
Selling, General & Admin100.06M129.26M151.39M161.77M171.47M
Operating Expenses104.03M139.83M171.85M343.93M40.13M
Depreciation & Amortization24.75M38.1M48.78M56.87M60.47M
EBITDA585.78M609.99M712.41M(156.92M)(147.51M)
EBITDA Margin73.3%69.1%246.6%-60.5%-79.4%
Operating Income554.65M574.22M(31.65M)(235.62M)(6.74M)
Operating Margin69.4%65.0%-11.0%-90.9%-3.6%
Interest Income02.34M27.73M27.4M23.95M
Interest Expense30.26M20.41M45.89M47.7M26.99M
Other Income / Expenses(23.88M)(22.74M)649.38M(25.87M)(228.24M)
Income Before Tax530.77M551.47M617.74M(261.48M)(234.97M)
Pre-Tax Margin66.4%62.5%213.8%-100.9%-126.5%
Income Tax Expense61.52M60.81M756.11M(1.86M)(4.21M)
Net Income182.04M220.21M(119.03M)(144.85M)(130.77M)
Net Margin22.8%24.9%-41.2%-55.9%-70.4%
EPS (Basic)1.591.67(0.90)(1.05)(0.91)
EPS (Diluted)1.561.67(0.90)(1.05)(0.91)
Weighted Avg Shares114.79M131.54M131.92M137.91M145.07M
Weighted Avg Shares (Diluted)121.97M131.7M131.92M137.91M145.07M

Maravai LifeSciences Holdings, Inc.

NASDAQ:MRVI

Intrinsic Alpha fair value

Locked

Current Price

$7.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.